Long-Term Outcomes of Ibrutinib in Chronic Lymphocytic Leukemia
Patients receiving ibrutinib had an overall response rate of 8% and median progression-free survival of 44.1 months.
Chronic Lymphocytic Leukemia
Combination Therapy May Improve Outcomes in Patients With Chronic Lymphocytic Leukemia
Patients receiving idelalisib experienced longer median overall survival compared with patients receiving placebo.
Chemotherapy-Free Combo Therapy Approved for Previously Untreated CLL
The FDA has approved Venclexta in combination with Gazyva for the treatment of patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Navigating Cancer Communication on Twitter
Twitter is increasingly being used by oncologists as a tool to communicate advancements in in the treatment of cancer. What could go wrong?
Tumor Lysis Syndrome in Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax
High risk for tumor lysis syndrome and creatinine clearance below 80 mL/min were associated with tumor lysis syndrome development.
“Another CAR in the Garage”: Q&A on CAR-T With UPenn’s Bruce Levine, PhD
Bruce Levine, PhD, explains why targeting multiple antigens simultaneously may be the most promising approach for adoptive cell therapies such as CAR-T.
Conditioning Chemotherapy Preceding CAR T-Cell Therapy Appears to Be Safe in Relapsed/Refractory CLL
Patients enrolled in a phase 1 trial receiving ibrutinib demonstrated augmented ex vivo CAR T-cell expansion.
Leukemia: What Your Patients Need to Know
Your patients may have questions about leukemia. Help them better understand the condition by sharing this article with them.
Current Standing and Future Directions of CAR T Therapy for Chronic Lymphocytic Leukemia
CAR T therapy has emerged in recent years as a feasible treatment for patients with chronic lymphocytic leukemia, but there are still many unanswered questions.
Expert Perspective: The Role of Ibrutinib and Venetoclax in Chronic Lymphocytic Leukemia
Hematology Advisor asked Prithviraj Bose, MD, to discuss the latest research on treatment options for CLL presented at the ASH 2018 Annual Meeting.
